Biodegradable stent proves non-inferior to drug-eluting stent

May 21, 2013, European Society of Cardiology

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine months in the results of an imaging substudy reported at EuroPCR 2013 today.

The BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical (OCT) to quantitatively assess neointimal and stent apposition at nine months after treating patients with symptomatic due to de novo stenotic lesions. Patients were randomly assigned to receive either the Orsiro (Biotronik) or the Xience Prime stent (Abbott Vascular). Images from baseline and the nine-month follow-up were analysed by independent and blinded core laboratories.

Results showed no difference in the angiographic endpoint of in-stent late lumen loss between the two stents at nine months (0.10+0.32mm with the Orsiro stent vs. 0.11 + 0.29mm with the Xience Prime stent, p non-=<0.0001). Rates of target lesion failure were also similar at nine months (4.8% vs. 5.3%, p=0.47).

The IVUS substudy showed somewhat less neointimal hyperplasia over nine months with the Orsiro stent (0.16) than the Xience stent (0.43, p=0.043) with 100% stent apposition. 
Similarly, neointimal area as assessed by OCT at nine months was somewhat less with the Orsiro stent (0.74+0.38mm2 ) than with the Xience stent (1.00+0.44mm2, p=0.024). The proportion of well-apposed struts was similar with the two stents and the proportion of covered struts was slightly higher with the Orsiro stent (98.3% vs. 97.5%, p=0.042).

Reporting the results, Stephan Windecker, Professor and Chief of Cardiology, Swiss Cardiovascular Center and Clinical Trials Unit Bern, Bern University Hospital, Switzerland, said, "The Orsiro -eluting stent with a was non-inferior to the Xience Prime everolimus-eluting stent with a durable polymer for the primary angiographic endpoint of in-state late loss at nine months in this prospective, randomised trial."

He added, " We need to be careful in interpreting the results of a trial set up for an angiographic endpoint but we can speculate that neointimal hyperplasia may be somewhat less with the Orsiro stent platform. And an important additional finding is that this potentially improved efficacy is not compromised by a lower proportion of uncovered struts. In addition, clinical event rates were low and comparable with both stents." Looking to the future, he concluded, "These results will need to be extended to larger randomised trials including more complex patients and powered for clinical endpoints."

Explore further: Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents

Related Stories

Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents

August 29, 2011
The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting ...

Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent

August 30, 2011
The second generation drug-eluting stent Xience V performs well in patients having primary PCI for ST elevation myocardial infarction, and has a better safety profile than that of bare metal stents, according to results of ...

New biolimus stent equal to everolimus stent at one year

March 11, 2013
In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today ...

Results of the REMEDEE trial reported at TCT 2011

November 11, 2011
A randomized comparison of a dual therapy stent – which combines low-dose sirolimus delivery from an abluminal biodegradable polymer matrix with a covalently bound anti-CD34 antibody layer – with a paclitaxel-eluting ...

Results of the EVOLVE trial reported at TCT 2011

November 11, 2011
A clinical trial has established the non-inferiority of a drug-eluting stent with a bioabsorbable polymer compared to a drug-eluting stent with a durable polymer. Results of the EVOLVE clinical trial were presented today ...

Recommended for you

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

Place of residence linked to heart failure risk

January 9, 2018
Location. Location. Location.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.